The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.
Drug: Lidocaine
Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
Inclusion Criteria:
- Covid-19 positive
- Moderate to severe ARDS
Exclusion Criteria:
- patients with COPD or taking bronchodilators and steroids for chronic respiratory
illnesses
Sheikh zayed medical college & hospital
Rahim Yar Khan, Punjab, Pakistan
Investigator: alina a umar, MCPS
Contact: 0092 689230165
alinaumar1@gmail.com
sairah s sadaf, FCPS
0092 689230165 - 245
sairahbabar@live.com